Prostate Cancer Market to Reach USD 21.45 Billion by 2031, Growing at 7.74% CAGR
By end-user, hospital pharmacies captured the largest share at 44.86% in 2023, reflecting their central role in ensuring timely patient access to complex oncology treatments and in optimizing medication management within healthcare facilities.
jhon Kary An aging global population and rapid advances in precision oncology are converging to reshape the treatment landscape for one of the most common cancers affecting men worldwide. The Prostate Cancer Market was valued at USD 11.94 billion in 2023 and is projected to grow from USD 12.72 billion in 2024 to USD 21.45 billion by 2031, reflecting a CAGR of 7.74% over the forecast period. This growth is being propelled by the rising global prevalence of the disease, expanding treatment options, and increased government funding supporting research and regulatory approvals.
Prostate cancer is a malignancy that develops in the prostate gland, typically progressing slowly and often presenting no symptoms in its early stages. In advanced cases, however, the disease can metastasize to other organs, posing significant health risks. Screening tools such as PSA testing and digital rectal exams support early detection, while treatment approaches range from active surveillance for low-risk cases to more intensive interventions including surgery, radiation therapy, hormone therapy, and chemotherapy for advanced disease.
Scale of the Clinical Challenge
The scale of prostate cancer's public health impact is significant. According to the American Cancer Society, approximately 268,490 new cases were diagnosed in the United States in 2022 alone, with an estimated 34,500 individuals expected to lose their lives to the disease. This procedural and diagnostic volume, replicated across major markets worldwide, continues to sustain robust demand for both diagnostic tools and therapeutic interventions.
Innovation Accelerating Treatment Options
Regulatory approvals continue to expand the therapeutic arsenal available to clinicians. In August 2023, the U.S. Food and Drug Administration granted approval to Janssen Biotech for Akeega, a fixed-dose combination of niraparib and abiraterone acetate used alongside prednisone, targeting adult patients with deleterious or suspected deleterious BRCA-mutated castration-resistant prostate cancer as confirmed by an FDA-approved test. Earlier, in March 2022, the FDA approved Novartis's Pluvicto for treating adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer, marking a significant milestone in radioligand therapy for the disease.
These approvals reflect a broader industry shift toward precision medicine, where biomarker testing and genomic profiling allow clinicians to tailor treatment strategies to individual patient characteristics, improving both treatment efficacy and prognosis. Collaborative research between pharmaceutical companies, academic institutions, and healthcare providers continues to accelerate the pace of innovation across the therapeutic pipeline.
Segment Performance
By drug class, hormonal ADT, or androgen deprivation therapy, led the market in 2023 with a valuation of USD 4.07 billion. As a fundamental treatment for advanced prostate cancer, ADT works by suppressing the androgen hormones that fuel cancer growth and remains widely prescribed both as a standalone therapy and in combination with radiation or chemotherapy. Continuous advancement in ADT formulations, including new drug delivery methods, continues to enhance efficacy while reducing side effects, further supporting segment growth.
By end-user, hospital pharmacies captured the largest share at 44.86% in 2023, reflecting their central role in ensuring timely patient access to complex oncology treatments and in optimizing medication management within healthcare facilities. As hospitals expand services and experience rising patient volumes, demand for pharmaceuticals and related support services provided through hospital pharmacy channels continues to grow correspondingly.
Regional Landscape
North America led the global market in 2023, commanding a 45.09% share valued at USD 5.38 billion. The region's advanced healthcare infrastructure, high healthcare expenditure, and favorable regulatory environment that facilitates faster drug approvals collectively support its market leadership. A growing aging population combined with rising chronic disease prevalence further reinforces sustained demand for prostate cancer treatments across the region.
Asia-Pacific is projected to post the strongest growth, expanding at a CAGR of 9.68% through the forecast period. An aging population and rising cancer incidence across the region are driving demand for advanced treatment options, while improving healthcare infrastructure and rising expenditure are enhancing access to both diagnostics and therapies. Government healthcare reform initiatives and growing partnerships between international pharmaceutical companies and local providers are further accelerating regional market expansion.
Competitive Landscape
The competitive landscape features several of the world's largest pharmaceutical companies, including Johnson & Johnson, Astellas Pharma, Eli Lilly, Sanofi, Ipsen Pharma, Bayer, AstraZeneca, Valeant Pharmaceuticals, Merck, and Pfizer. These companies continue to pursue partnerships, mergers and acquisitions, and product innovation to expand treatment portfolios and strengthen market position.
A notable development came in November 2023, when Astellas Pharma and Pfizer announced FDA approval for a supplemental New Drug Application for XTANDI, following expedited review pathways including Priority Review, Fast Track designation, and Real-time Oncology Review based on results from the Phase 3 EMBARK trial. This approval made XTANDI the first androgen receptor signaling inhibitor approved for treating nonmetastatic castration-sensitive prostate cancer patients with biochemical recurrence at high risk of metastasis, whether used alone or alongside GnRH analog therapy.
Navigating Treatment Complexity
Variability in treatment outcomes and the inherent complexity of predicting disease progression remain significant challenges facing the market. These factors introduce uncertainty into treatment decision-making, prompting industry stakeholders to invest heavily in precision medicine approaches that leverage biomarker testing and genomic profiling to personalize care. Collaborative research efforts between institutions and pharmaceutical companies continue to focus on developing predictive models and innovative therapies aimed at improving overall disease management.
Outlook
With an aging global population, expanding screening initiatives, and a rapidly advancing therapeutic pipeline anchored in precision medicine, the prostate cancer market is well positioned for sustained growth through 2031. Continued regulatory support for expedited drug approvals, combined with rising government investment in cancer research, should further accelerate the introduction of innovative treatment options, ultimately improving outcomes and quality of life for patients worldwide.
